InfertilityNCT04190732
Impact of Physician Contact on Patient Anxiety During the Waiting Period After Embryo Transfer
A study testing Physician phone call in people with Infertility, run by Boston IVF at 1 site in United States.
Trial summary
This will be a randomized controlled trial to compare if physician contact within the period from embryo transfer to serum pregnancy test decreases anxiety levels for first-time IVF patients. Read more about this study
- Who is it for?
- Ages 18 to 43 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Infertility
- What is being tested?
- Physician phone call
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 231 participants
- Where
- 1 siteUnited States
- Study dates
- 6 Jan 2020to Jun 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 43 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- First IVF cycle
- Autologous cycle
- 18 - 43 years of age
Who cannot join
- Utilizing a gestational carrier
- Preimplantation Genetic Testing for chromosome structural rearrangements (PGT- SR)
- Preimplantation Genetic Testing for Single gene (monogenic) (PGT-M)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Impact of Physician Contact on Patient Anxiety and Distress During the Waiting Period After Embryo Transfer: a Randomized Controlled Study
This will be a randomized controlled trial to compare if physician contact within the period from embryo transfer to serum pregnancy test decreases anxiety levels for first-time IVF patients.
Read the detailed description
Overview This will be a randomized controlled trial to compare if physician contact within the period from embryo transfer to first pregnancy test decreases anxiety levels for first-time IVF patients.
Methods Study participation will not influence any element of IVF treatment, and all patients will be receiving the standard of care at Boston IVF. Potential participants will be identified by a member of the research team, who will review the appointment log and medical records to ensure eligibility. Participants who meet eligibility criteria will receive an email introduction to the study on the first stimulation day of the cycle and participants will be asked if interested in participating. Interested participants can click a secure REDCap link to learn more about that study. Participants who agree to participate will be directed via a unique link for each participant to a REDCap survey to complete a baseline questionnaire prior to the first ultrasound monitoring (T1), which is normally day 3 to 6 of IVF stimulation. Participants that complete the baseline survey are consenting for the study. Baseline demographic data will be obtained from the electronic medical record including: age, race, education level, partner status, height, weight, gravidity, and parity. Baseline clinical data, including anti-mullerian hormone and day 3 follicle stimulating hormone levels, will be obtained from the electronic medical record. The baseline survey will include demographic questions, the state-trait anxiety inventory (STAI), and the Hospital Anxiety and Depression Scale (HADS). STAI and HADS are two validated surveys used widely when examining anxiety in patients. The STAI is comprised of the trait and state questions. After stimulation day 3, a reminder email will be sent to eligible participants via REDCap to introduce the study again with a follow up phone call on stimulation day 4, if needed. Given the quick turnaround time from stimulation day 1 to first ultrasound monitoring (stimulation day 3 to 6), the additional email/phone contact schedule is necessary. If participants do not complete the baseline survey in entirety, participants will not be eligible for randomization. Participants will need to complete the survey in one sitting. Randomization will only occur if participants have an embryo transfer and complete the baseline survey. If selected to the intervention arm, participants will be called by one physician 3 to 4 days after the embryo transfer. Participants will be informed that the physician contact is not the participants specific doctor of record and that the physician contact will not be able to answer specific questions about the participants treatment cycle.
All participants that have an embryo transfer (fresh or frozen) will have a scheduled serum beta-hCG 10-12 days after the date of transfer. Eight days after the transfer (T2), participants will receive a second survey that will only include the STAI - state and HADS to be completed prior to the first serum beta-hCG. If participants have not started the survey by 9 days after the transfer, the participant will receive a reminder email on stimulation day 9 in the morning followed by a phone call on stimulation day 9 in the evening if needed for a reminder to complete the survey. The participant has the option to withdraw from the study at any time by notifying the research team by email or phone.
Intervention Participants will receive routine care or an approximately five-minute phone call from a physician 3 to 4 days after a fresh or frozen embryo transfer. The physician will state they are a part of the research team. For participants that do not answer the phone, a message will be left stating the participant will receive another phone call that same day and once more the following day if the participant does not answer on the second attempt. The phone call will follow scripted questions and utilize scripted phrases to help minimize variation.
Randomization Participants undergoing a fresh embryo transfer or planned frozen embryo transfer/PGT-A are eligible for inclusion in the study. Participants will be block-randomized by type of transfer to ensure balance between the intervention and control groups. The randomization scheme will be generated via REDCap. If participants are randomized to the intervention arm, participants will know this only if the participant receives a physician phone call during the waiting period after embryo transfers. All participants, regardless of transfer type, will be randomized only after participants have an embryo transfer.
Sample Size Justification The sample size calculation is based on data from a prior study that evaluated stress throughout the course of a IVF cycle using the STAI. The mean STAI-S in the infertility population ranges from 33-50, with Turner et al. reporting a mean STAI-S score of 40 ± 12. Assuming that the mean STAI-S score in the control group will be 40 ± 12 at the second time point, the investigators hypothesize that the mean STAI-S at this point in the intervention group will decrease to 35 ± 12. In order to achieve 80% power to detect the specified difference using a two-sided alpha of 0.05, the investigators will need 91 evaluable participants per arm. The Investigators anticipate that approximately 15% of participants will not complete the second survey, and the investigators will inflate the sample size by another 15% to account for a non-normal distribution. Thus, the investigators aim to randomize 121 participants per arm for a total of 242 participants.
Data Analysis Descriptive data will be presented as the proportion, mean with standard deviation, or median with interquartile range. Comparisons will be made using the chi-square or Fisher's exact test for categorical variables and parametric or non-parametric tests for continuous variables based on data distribution. All data will be analyzed with SAS 9.4 (SAS Institute Inc., Cary, NC, USA). All tests will be two sided and a P value <0.05 will be required to confer significance.
- Conditions
- Infertility
- Being tested
- Physician phone call
- Keywords
- infertility, in-vitro fertilization (IVF), anxiety, distress
- Medical subject headings
- Infertility, Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Physician phone callBehavioural
Often, patients will not have contact with a physician during the waiting period between embryo transfer and the pregnancy test. Participants in the intervention group will receive a phone call from one physician 3 to 4 days after fresh or frozen embryo transfer to check in. The physician will introduce themselves and state they are a part of the research team.
| Study group | Role | What they receive |
|---|---|---|
| Physician phone call | Experimental | Participants will receive a five-minute phone call from one physician 3 to 4 days after a fresh or frozen embryo transfer. The physician will not have access to patient specific IVF cycle details. The phone call will follow scripted questions and utilize scripted phrases to help minimize variation. Receives: Behavioral: Physician phone call |
| Routine care | No intervention | Participants will receive routine care and no physician phone call will be performed during the waiting period between embryo transfer and the pregnancy test. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in anxiety levels from two time points in an IVF cycle measured by the State Trait Anxiety Inventory - State (STAI-S) survey
The investigators will assess change in anxiety levels from T1 to T2 using the State Trait Anxiety Inventory - State survey. A lower score on the State Trait Anxiety Inventory - State at T2 signifies a decrease in anxiety levels for a participant. The minimum and maximum score on the State Trait Anxiety Inventory - State is 20 and 80.
Measured: Completed twice: once between IVF stimulation days 1-4 (T1) and again 8 days after (T2) embryo transfer and before first pregnancy test
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Dec 2019
- Study start6 Jan 2020
- Primary completion6 Jan 2021
- Study completionJun 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for InfertilityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 231 participants (actual)
Sponsor and investigators
- Lead sponsor
- Boston IVF
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Alan Penzias, MD, Principal investigator, Boston IVF
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04190732
- Sponsor's protocol ID
- 2019P000939
- Status last verified
- Mar 2022
- First submitted
- 26 Nov 2019
- Last updated
- 11 Mar 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Mar 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Physician Contact on Patient Anxiety and Distress During the Waiting Period After Embryo Transfer: a Randomized Controlled Study
- ClinicalTrials.gov ID
- NCT04190732
- Acronym / sponsor ID
- 2019P000939
- Conditions
- Infertility
- Keywords
- infertility, in-vitro fertilization (IVF), anxiety, distress
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 231 participants (actual)
- Lead sponsor
- Boston IVFUniversity, hospital or other
- Study start
- 6 Jan 2020 (actual)
- Primary completion
- 6 Jan 2021 (actual)
- Study completion
- Jun 2022 (estimated)
- First posted
- 9 Dec 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This will be a randomized controlled trial to compare if physician contact within the period from embryo transfer to serum pregnancy test decreases anxiety levels for first-time IVF patients.
Detailed description
Overview This will be a randomized controlled trial to compare if physician contact within the period from embryo transfer to first pregnancy test decreases anxiety levels for first-time IVF patients.
Methods Study participation will not influence any element of IVF treatment, and all patients will be receiving the standard of care at Boston IVF. Potential participants will be identified by a member of the research team, who will review the appointment log and medical records to ensure eligibility. Participants who meet eligibility criteria will receive an email introduction to the study on the first stimulation day of the cycle and participants will be asked if interested in participating. Interested participants can click a secure REDCap link to learn more about that study. Participants who agree to participate will be directed via a unique link for each participant to a REDCap survey to complete a baseline questionnaire prior to the first ultrasound monitoring (T1), which is normally day 3 to 6 of IVF stimulation. Participants that complete the baseline survey are consenting for the study. Baseline demographic data will be obtained from the electronic medical record including: age, race, education level, partner status, height, weight, gravidity, and parity. Baseline clinical data, including anti-mullerian hormone and day 3 follicle stimulating hormone levels, will be obtained from the electronic medical record. The baseline survey will include demographic questions, the state-trait anxiety inventory (STAI), and the Hospital Anxiety and Depression Scale (HADS). STAI and HADS are two validated surveys used widely when examining anxiety in patients. The STAI is comprised of the trait and state questions. After stimulation day 3, a reminder email will be sent to eligible participants via REDCap to introduce the study again with a follow up phone call on stimulation day 4, if needed. Given the quick turnaround time from stimulation day 1 to first ultrasound monitoring (stimulation day 3 to 6), the additional email/phone contact schedule is necessary. If participants do not complete the baseline survey in entirety, participants will not be eligible for randomization. Participants will need to complete the survey in one sitting. Randomization will only occur if participants have an embryo transfer and complete the baseline survey. If selected to the intervention arm, participants will be called by one physician 3 to 4 days after the embryo transfer. Participants will be informed that the physician contact is not the participants specific doctor of record and that the physician contact will not be able to answer specific questions about the participants treatment cycle.
All participants that have an embryo transfer (fresh or frozen) will have a scheduled serum beta-hCG 10-12 days after the date of transfer. Eight days after the transfer (T2), participants will receive a second survey that will only include the STAI - state and HADS to be completed prior to the first serum beta-hCG. If participants have not started the survey by 9 days after the transfer, the participant will receive a reminder email on stimulation day 9 in the morning followed by a phone call on stimulation day 9 in the evening if needed for a reminder to complete the survey. The participant has the option to withdraw from the study at any time by notifying the research team by email or phone.
Intervention Participants will receive routine care or an approximately five-minute phone call from a physician 3 to 4 days after a fresh or frozen embryo transfer. The physician will state they are a part of the research team. For participants that do not answer the phone, a message will be left stating the participant will receive another phone call that same day and once more the following day if the participant does not answer on the second attempt. The phone call will follow scripted questions and utilize scripted phrases to help minimize variation.
Randomization Participants undergoing a fresh embryo transfer or planned frozen embryo transfer/PGT-A are eligible for inclusion in the study. Participants will be block-randomized by type of transfer to ensure balance between the intervention and control groups. The randomization scheme will be generated via REDCap. If participants are randomized to the intervention arm, participants will know this only if the participant receives a physician phone call during the waiting period after embryo transfers. All participants, regardless of transfer type, will be randomized only after participants have an embryo transfer.
Sample Size Justification The sample size calculation is based on data from a prior study that evaluated stress throughout the course of a IVF cycle using the STAI. The mean STAI-S in the infertility population ranges from 33-50, with Turner et al. reporting a mean STAI-S score of 40 ± 12. Assuming that the mean STAI-S score in the control group will be 40 ± 12 at the second time point, the investigators hypothesize that the mean STAI-S at this point in the intervention group will decrease to 35 ± 12. In order to achieve 80% power to detect the specified difference using a two-sided alpha of 0.05, the investigators will need 91 evaluable participants per arm. The Investigators anticipate that approximately 15% of participants will not complete the second survey, and the investigators will inflate the sample size by another 15% to account for a non-normal distribution. Thus, the investigators aim to randomize 121 participants per arm for a total of 242 participants.
Data Analysis Descriptive data will be presented as the proportion, mean with standard deviation, or median with interquartile range. Comparisons will be made using the chi-square or Fisher's exact test for categorical variables and parametric or non-parametric tests for continuous variables based on data distribution. All data will be analyzed with SAS 9.4 (SAS Institute Inc., Cary, NC, USA). All tests will be two sided and a P value <0.05 will be required to confer significance.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Physician phone call | Experimental | Behavioral: Physician phone callParticipants will receive a five-minute phone call from one physician 3 to 4 days after a fresh or frozen embryo transfer. The physician will not have access to patient specific IVF cycle details. The phone call will follow scripted questions and utilize scripted phrases to help minimize variation. |
| Routine care | No intervention | –Participants will receive routine care and no physician phone call will be performed during the waiting period between embryo transfer and the pregnancy test. |
Who may qualify
- Ages
- 18 to 43 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- First IVF cycle
- Autologous cycle
- 18 - 43 years of age
Key exclusion criteria (3 listed)
- Utilizing a gestational carrier
- Preimplantation Genetic Testing for chromosome structural rearrangements (PGT- SR)
- Preimplantation Genetic Testing for Single gene (monogenic) (PGT-M)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Physician phone callOften, patients will not have contact with a physician during the waiting period between embryo transfer and the pregnancy test. Participants in the intervention group will receive a phone call from one physician 3 to 4 days after fresh or frozen embryo transfer to check in. The physician will introduce themselves and state they are a part of the research team. | Behavioural | Physician phone call |
Primary outcome
Change in anxiety levels from two time points in an IVF cycle measured by the State Trait Anxiety Inventory - State (STAI-S) survey
Time frame: Completed twice: once between IVF stimulation days 1-4 (T1) and again 8 days after (T2) embryo transfer and before first pregnancy test
The investigators will assess change in anxiety levels from T1 to T2 using the State Trait Anxiety Inventory - State survey. A lower score on the State Trait Anxiety Inventory - State at T2 signifies a decrease in anxiety levels for a participant. The minimum and maximum score on the State Trait Anxiety Inventory - State is 20 and 80.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Mar 2022.
- Individual participant dataSharing planned: No
Related trials for Infertility
RecruitingObservational study
International Pilot Study for Dual Non-invasive Assesment of Embryo Development
Infertility
Active, not recruitingObservational study
Retrieval of Sperm From Men With Azoospermia Using Ultrasound-guided Rete Testis Aspiration
Azoospermia, Nonobstructive, Infertility, Male
Not yet recruiting
Spinery Basivertebral Nerve Ablation for Vertebrogenic Chronic Low Back Pain
Low Back Pain, Chronic Low Back Pain (CLBP)
RecruitingObservational study
Impact of Infertility on the Sexual Sphere in Couples Undergoing Assisted Reproduction
Sexual Health Quality of Life, Infertile Patients
RecruitingObservational study
Pilot Study of Discarded Blastocysts
Infertility (IVF Patients)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alan Penzias, MD principal investigator
Boston IVF
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Physician phone call in people with Infertility, run by Boston IVF at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 11 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in anxiety levels from two time points in an IVF cycle measured by the State Trait Anxiety Inventory - State (STAI-S) survey (time frame: Completed twice: once between IVF stimulation days 1-4 (T1) and again 8 days after (T2) embryo transfer and before first pregnancy test). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Mar 2022.